Stock Analysis
- China
- /
- Medical Equipment
- /
- SZSE:301371
Investors Aren't Buying Harbin Fuerjia Technology Co., Ltd.'s (SZSE:301371) Earnings
With a price-to-earnings (or "P/E") ratio of 20.6x Harbin Fuerjia Technology Co., Ltd. (SZSE:301371) may be sending bullish signals at the moment, given that almost half of all companies in China have P/E ratios greater than 39x and even P/E's higher than 77x are not unusual. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/E.
With its earnings growth in positive territory compared to the declining earnings of most other companies, Harbin Fuerjia Technology has been doing quite well of late. It might be that many expect the strong earnings performance to degrade substantially, possibly more than the market, which has repressed the P/E. If not, then existing shareholders have reason to be quite optimistic about the future direction of the share price.
See our latest analysis for Harbin Fuerjia Technology
Is There Any Growth For Harbin Fuerjia Technology?
In order to justify its P/E ratio, Harbin Fuerjia Technology would need to produce sluggish growth that's trailing the market.
If we review the last year of earnings, the company posted a result that saw barely any deviation from a year ago. Whilst it's an improvement, it wasn't enough to get the company out of the hole it was in, with earnings down 29% overall from three years ago. Therefore, it's fair to say the earnings growth recently has been undesirable for the company.
Looking ahead now, EPS is anticipated to climb by 2.0% during the coming year according to the seven analysts following the company. Meanwhile, the rest of the market is forecast to expand by 37%, which is noticeably more attractive.
In light of this, it's understandable that Harbin Fuerjia Technology's P/E sits below the majority of other companies. It seems most investors are expecting to see limited future growth and are only willing to pay a reduced amount for the stock.
The Final Word
Using the price-to-earnings ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.
We've established that Harbin Fuerjia Technology maintains its low P/E on the weakness of its forecast growth being lower than the wider market, as expected. At this stage investors feel the potential for an improvement in earnings isn't great enough to justify a higher P/E ratio. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.
The company's balance sheet is another key area for risk analysis. Our free balance sheet analysis for Harbin Fuerjia Technology with six simple checks will allow you to discover any risks that could be an issue.
If these risks are making you reconsider your opinion on Harbin Fuerjia Technology, explore our interactive list of high quality stocks to get an idea of what else is out there.
Valuation is complex, but we're here to simplify it.
Discover if Harbin Fuerjia Technology might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:301371
Harbin Fuerjia Technology
Engages in the research, development, production, and sale of skin care products in China.